Prism Ai
3 known investors
Prism AI builds an AI platform for biomarker discovery and drug development from multi-omics clinical trial data.
Also known as Prism AI
Investors · 3
Company profile
researched Aug 2026Prism AI is a software company developing what it describes as an operating system for drug development and biomarker discovery. Its cloud platform applies an AI approach built for biomarker discovery from real-world clinical trial data, with the aim of supporting personalized medicine by detecting and targeting complex multi-omics signatures.
The company is categorized in life sciences and drug development, with activity spanning biomarkers, genomics, quantum computing and AI-driven drug discovery, and operates a business-to-business model. Public directory listings place its headcount at approximately four people.
Business model
Business-to-business, selling a cloud computing platform to organizations engaged in drug development and clinical research.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned among AI-driven biomarker discovery and drug development companies; directory comparisons list peers such as QuantHealth, Protai, Curesponse, POLARISqb and PhaseV.
Technology
A cloud computing platform using an AI approach designed for biomarker discovery from real-life clinical trial data, oriented toward detecting and targeting complex multi-omics signatures for personalized medicine.
Go-to-market
Drug developers and clinical research organizations working with clinical trial and multi-omics data.
Geography
Listings place the company in the United States, variously identified as San Francisco, California and Salt Lake City, Utah.
History
Directory records date the company's founding to 2024. Its founding team comprises chief executive and co-founder Asaf Zviran, previously co-founder, CEO and CSO of C2i Genomics; chief scientific officer and co-founder Orly Alter, a University of Utah professor known as the inventor of the "Eigengene"; and chief technology officer and co-founder Daniel Shabtai, formerly an engineering leader at Facebook/Meta. Additional leadership includes a fractional chief business officer, a fractional VP of finance and a VP of product.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 7
primary sources listed
- Prism AI Feature Overview – Prism Support Centerbuildingengines-prism.zendesk.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Prism Ai do?
- Prism AI builds an AI platform for biomarker discovery and drug development from multi-omics clinical trial data.
- Who are Prism Ai's investors?
- Prism Ai's investors include Evolution VC Partners, Utah Innovation Fund, Vela Partners.